We are live on
!
Find out more
IMUC
ImmunoCellular Therapeutics, Ltd.
IMUC
IMUC
Delisted
IMUC was delisted on the 16th of October, 2018.
36 hedge funds and large institutions have $2.77M invested in ImmunoCellular Therapeutics, Ltd. in 2016 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
6% more funds holding
Funds holding: 34 → 36 (+2)
17% less capital invested
Capital invested by funds: $3.35M → $2.77M (-$577K)
Holders
36
Holders Change
+2
Holders Change %
+5.88%
% of All Funds
0.96%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
9
Reduced
7
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Goldman Sachs
New York
|
+$12.5K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$10.5K |
| 3 |
Bank of New York Mellon
New York
|
+$6.05K |
| 4 |
Nomura Holdings
Tokyo,
Japan
|
+$5.7K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
+$2.59K |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
-$22.4K |
| 2 |
Renaissance Technologies
New York
|
-$6.24K |
| 3 |
LPL Financial
San Diego,
California
|
-$4K |
| 4 |
CCC
Chelsea Counsel Company
Los Angeles,
California
|
-$514 |
| 5 |
Citigroup
New York
|
-$154 |
